Delivery Order SPE2DB22D2007-SPE2DB25FJ4CS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,720.78 to AmerisourceBergen Drug Corp for the supply of Rexulti (brexpiprazole) 2 mg tablets in a quantity of 30 units. This firm fixed price delivery order, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate office. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,846.60 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. The award was issued on September 23, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $4,195.59 by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Rexulti 2 mg tablets (30-count packages). The contract carries a firm fixed price structure with no set-aside designation, indicating the award was made through open competition. The order is scheduled for completion by September 10, 2025, with performance conducted from the vendor's Corporate Office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,697.80 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle extending through December 2026....
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $11,846.76 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical delivery order and functions as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,492.36 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of August 8, 2025, one day following the August 7, 2025 award date. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor on this...
- The Defense Logistics Agency awarded a delivery order valued at $7,465.18 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 4 mg on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a pharmaceutical supply fulfillment under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,278.42 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The pharmaceutical product will be delivered to the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4CSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,723.01 to AmerisourceBergen Drug Corp for the supply of Rexulti (brexpiprazole) 2 mg tablets in a 30-count package. The contract is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, and was competitively awarded without set-aside designation. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs and other federal healthcare systems worldwide. Rexulti, an atypical antipsychotic medication, represents the type of specialty pharmaceutical products within the contract's scope to support Defense Health Agency requirements and other federal medical supply chain needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/19/25 |